p53 Antibodies in Patients with Various Types of Cancer: Assay, Identification, and Characterization

Clinical Cancer Research

Volumn 1, Issue 12, 1995, Pages 1463-1469

  Lubin, Richard ^a   Schlichtholz, Beata ^a   Teillaud, Jean Luc ^a   Garay, Edith ^a   Bussel, Annette ^b   Wild, Christopher P ^c   Soussi, Thierry ^a  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ANTIBODY BLOOD LEVEL; ARTICLE; CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0029618905     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Caron de Fromentel, C., and Soussi, T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes & Cancer, 4: 1–15, 1992.
2. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC) 253: 49–53, 1991.
3. Remvikos, Y., Tominaga, O., Hammel, P., Laurent-Puig, P., Salmon, R. J., Dutrillaux, B., and Thomas, G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br. J. Cancer, 66: 758–764, 1992.
4. Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L. C., Mayall, B. H., and Smith, H. S. Accumulation of p53 tumor suppressor gene protein—an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845–855, 1992.
5. Starzynska, T., Bromley, M., Ghosh, A., and Stem, P. L. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br. J. Cancer, 66: 558–562, 1992.
6. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957–967. 1993.
7. Soussi, T., Legros, Y., Lubin, R., Ory, K., and Schlichtholz, B. Multifactorial analysis of p53 alteration in human cancer—a review. Int. J. Cancer, 57: 1–9, 1994.
8. Crawford, L. V., Pirn, D. C., and Bulbrook, R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30: 403–408, 1982.
9. Caron de Fromentel, C., May-Levin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K., and May, P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39: 185–189, 1987.
10. Davidoff, A. M., Iglehart, J. D., and Marks, J. R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl. Acad. Sci. USA, 89: 3439–3442. 1992.
11. Schlichtholz, B., Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D., Calvo, F., and Soussi, T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res., 52: 6380–6384, 1992.
12. Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gazdar, A. F., and Carbone, D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res, 52: 4168–4174. 1992.
13. Angelopoulou, K., Diamandis, E. P., Sutherland, D. J. A., Kellen, J. A., and Bunting, P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer, 58: 480–487, 1994.
14. Marxsen, J., Schmiegel, W., Roder, C., Harder, R., Juhl, H., Hennebruns, D., Kremer, B., and Kalthoff, H. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br. J. Cancer, 70: 1031–1034, 1994.
15. Preudhomme, C., Lubin, R., Lepelley, P., Vanrumbeke, M., and Fenaux, P. Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia (Baltimore), 8: 1589–1591, 1994.
16. Wild, C. P., Ridanpaa, M., Anttila, S., Lubin, R., Soussi, T., Husgafvel-Pursiainen, K., and Vainino, H. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int. J. Cancer, 64: 176–181, 1995.
17. Guinee, D. G., Travis, W. D., Trivers, G. E., Debenedetti, V. M. G., Cawley, H., Welsh, J. A., Bennett, W. P., Jett, J., Colby, T. V., Tazelaar, H., Abbondanzo, S. L., Pairolero, P., Trastek, V., Caporaso, N. E., Liotta, L. A., and Harris, C. C. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis, 16: 993–1002, 1995.
18. Mudenda, B., Green, J. A., Green, B., Jenkins, J. R., Robertson, L., Tarunina, M., and Leinster, S. J. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br. J. Cancer, 69: 1115–1119, 1994.
19. Peyrat, J. P., Bonneterre, J., Lubin, R., Vanlemmens, L., Fournier, J., and Soussi, T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet, 345: 621–622, 1995.
20. Lubin, R., Zalcman, G., Bouchet, L., Tredaniel, J., Legros, Y., Cazals, D., Hirsh, A., and Soussi, T. Serum p53 antibodies as early markers of lung cancer. Nat. Med., 1: 701–702, 1995.
21. Schlichtholz, B., Tredaniel, J., Lubin, R., Zalcman, G., Hirsch, A., and Soussi, T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer, 69: 809–816, 1994.
22. Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Tredaniel, J., Hirsch, A., Caron de Fromentel, C., Preudhomme, C., Fenaux, P., Fournier, G., Mangin, P., Laurent-Puig, P., Pelletier, G., Schlumberger, M., Desgrandchamps, F., Leduc, A., Peyrat, J. P., Janin, N., Bressac, B., and Soussi, T. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res., 53: 5872–5876, 1993.
23. Vojtesek, B., Kovarik, J., Dolezalova, H., Nenutil, R., Havlis, P., Brentani, R. R., and Lane, D. P. Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br. J. Cancer, 71: 1253–1256, 1995.
24. Jeffries, R., Reimer, C. B., Skvrail, F., de Lange, G., Ling, N. R., Lowe, J., Walker, M. R., Phillips, D. J., Aloisio, C. H., Wells, T. W., Vaerman, J. P., Magnuson, C. G., Kubagawa, H., Cooper, M., Vardtal, F., Vandvik, B., Haaijman, J. J., Makeda, O., Samesto, A., Lando, Z., Gergely, J., Radi, J., and Molinaro, G. A. Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of an IUISAVHO collaborative study. Immunol. Lett., 10: 223–252, 1985.
25. Legros, Y., Lafon, C., and Soussi, T. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene, 9: 2071–2076, 1994.
26. Soussi, T., Caron de Fromentel, C., Stiirzbecher, H. W., Ullrich, S., Jenkins, J., and May, P. Evolutionary conservation of the biochemical properties of p53-specific interaction of Xenopus-laevis p53 with simian virus 40 large T-antigen and mammalian heat shock proteins-70. J. Virol., 63: 3894–3901, 1989.
27. Kress, M., May, E., Cassingena, R., and May, P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 serum. J. Virol., 31: 472–483, 1979.
28. De Leo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., and Old, L. J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA, 76: 2420–2424, 1979.
29. Rotter, V., Witte, O. N., Coffman, R., and Baltimore, D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, p 50. J. Virol., 36: 547–555, 1980.
30. Volkmann, M., Muller, M., Hofmann, W. J., Meyer, M., Hagelstein, J., Rath, U., Kommerell, B., Zentgraf, H., and Galle, P. R. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology, 18: 559–565, 1993.
31. Andersen, T. I., Holm, R., Nesland, J. M., Heimdal, K. R., Ottestad, L., and Borresen, A. L. Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer, 68: 540–548, 1993.
32. Moll, U. M., Riou, G., and Levine, A. J. Two distinct mechanisms alter p53 in breast cancer—mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262–7266, 1992.